Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KFASN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IgG-P1-L12-P4
|
|||||
| Synonyms |
Ab-P1-L1-P1
Click to Show/Hide
|
|||||
| Organization |
NOVARTIS AG
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
P4 payload
|
Payload Info | ||||
| Linker Name |
L12 linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 3.05 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
lgG-P1-L12-P4 was tested in KMS-27
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KMS-27 cells | CVCL_2993 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 20.47 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
lgG-P1-L12-P4 was tested in RL
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | RL cells | CVCL_1660 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 50 nM | High CD48 expression (CD48 +++) | ||
| Method Description |
lgG-P1-L12-P4 was tested in KHM-1B
|
||||
| In Vitro Model | Plasma cell myeloma, Multiple myeloma | KHM-1B cells | CVCL_2972 | ||